Share Name Share Symbol Market Type Share ISIN Share Description
Circassia Pharmaceuticals Plc LSE:CIR London Ordinary Share GB00BJVD3B28 ORD 0.08P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 16.50p 16.40p 16.60p 16.50p 16.00p 16.40p 108,123 15:34:11
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 48.3 -55.8 -34.0 - 62

Circassia Pharmaceuticals Share Discussion Threads

Showing 1301 to 1325 of 1325 messages
Chat Pages: 53  52  51  50  49  48  47  46  45  44  43  42  Older
DateSubjectAuthorDiscuss
01/10/2019
16:15
A very good entry price SpectoAcc.
the abbot
01/10/2019
16:00
Director - 300k shares Richard Griffiths - 94,445,265 shares. One's close to the business, the other isn't. Just sayin'. The market always looks ahead - I agree. I'd suggest it doesn't particularly like what it sees with CIR, and the distant years in that note tends to confirm it. But I'll admit - I'm finally in for a few. Don't expect me to be any less sceptical.
spectoacc
01/10/2019
15:51
Well I guess you need to think future, no point buying in when they have already made it. Todays price may not be the very lowest they have been, but it's near as damn it, I see more upside from here than down, so just playing the game. much like the director above. Even Directors don't throw £50k around unless they think there's a profit in it for them.
the abbot
01/10/2019
14:16
I admire your "glass half full" @the abbot. I read the above note and picked out: 1. No profit until 2021 and then only if everything goes right 2. Even assuming it does, loan not paid back until 2024 Any miss of that £75m EBITDA target and everything pushed back still further. Still - what's in the price? Something, but not nothing.
spectoacc
01/10/2019
11:56
50k director purchase, about time...
rathean
01/10/2019
11:40
Director Purchase 300,000 @ 16.5p https://www.londonstockexchange.com/exchange/news/market-news/market-news-detail/CIR/14249110.html
the abbot
27/9/2019
08:38
Well this is a nice read, see the Finncap note, pretty much supports why I am buying at these levels. Initiation report: interims clarify misperceptions Circassia is a specialty pharmaceutical company, focused on respiratory disease, with three approved products in the US and one that is soon to be filed at the FDA. Operational leverage, given the largely fixed infrastructural costs already in place, c.27% CAGR 2019-2024 revenue forecast and a deleveraging balance sheet should drive substantial incremental value in our opinion. The interim results point to this, with period-end cash of £21m and positive EBITDA targeted on £75m of annual sales (ie. in 2020). We initiate with a target price of 80p, which implies the stock trading on a 2021EV/Sales multiple of 3.7x and includes first full-year sales of Duaklir. The prospect of LungFit PHapproval and launch in 2020 and profitability in 2021 is expected to drive the target higher in months to come as management executes on its strategy. Commercial stage spec pharma. Focused on respiratory disease with a valuable commercial infrastructure of c.200in the US and c.100 in China, Circassia is well positioned to drive substantial revenue growth over the next five years from three FDA-approved products and a further product that will be filed shortly with FDA. Interims indicate cashflow breakeven to occur earlier than previously expected. Market concerns of a cash call can be put to bed. Period end cash was £21m, with £19.8m at 31 August demonstrating a dramatically reduced H2 cash outflow and underpinning targeted EBITDA-positive position at £75m of annual sales. Product portfolio to drive substantial value. Four products, three of which are approved by the FDA, are expected to drive revenues by 27% pa from 2019-24 with the capacity to all be c.£50m+ products. NIOX, anasthma diagnostic, is the gold standard test; Tudorza and Duaklir, two products for COPD are supported by GOLD prescribing guidelines with differentiated prescribing labels and LungFit PH, a treatment for pulmonary hypertension in new born children, which should be filed with the FDA in Q4,is expected to launch in H2 2020. Forecasts. We forecast 2-year revenue growth of 32% pa, with c.£207m of revenues in 2024, becoming cashflow positive in 2020 and profitable in 2021, driven by operational leverage afforded by its established commercial infrastructure. We forecast cumulative free cashflow of c.£140m to fully de-leverage the balance sheet enabling the company to repay its $143.3m loan from AstraZeneca in full in 2024. Valuation. We initiate with a target price of80p, which implies the stock trading on 2021 EV/Sales of 3.7x.Should the company deliver on our forecasts, the prospect of a 175p price target in 2023 (implying prospective 2.8x EV/Sales) is realistic. hTTps://researchlibrary.finncap.com/File/View?file=f701a6de-6a2a-4983-9ea3-e963ecbd128a
the abbot
26/9/2019
14:47
I probably have more losers than winners but my motto is as soon as something feels uncomfortable then sell. You can always buy back and pay a bit more if necessary. Take the losses quickly and run the profits it's built me a tidy 6 figure sum from less than a ten grand starting stake.
basem1
26/9/2019
14:36
Agreed. I have a couple that have become a long term cause. I'm a sucker for a good story from a believable CEO.My only hope on this share is that the price was 4 times this with just the promise of the astra deal.All that has happened, so have had to give him a chance.Good luck to you all.P.S thanks to all the posters on this board that have contributed in a thoughtful informative way, it makes a nice change from some of the boards.
aspringo
26/9/2019
14:13
No stop losses aspringo - way to the poorhouse that ?
basem1
26/9/2019
13:15
Edit: passed...oops.See its going well.
aspringo
26/9/2019
10:07
Have held from 60 pence, so happy to hold from here.Though i may have past away before i ever see a profit.Cheers for all the posts gents.
aspringo
26/9/2019
10:05
He looks a happy man in that video, thanks for sharing.
the abbot
26/9/2019
09:42
https://www.proactiveinvestors.co.uk/companies/news/903532/circassia-pharmaceuticals-sets-out-its-road-map-to-profitability-903532.html ... and interview with Steve Harris at https://www.proactiveinvestors.co.uk/companies/news/903546/circassia-pharmaceuticals--commercial-development--accelerating-significantly--903546.html
zho
26/9/2019
09:10
Circassia Pharmaceuticals sets out its road-map to profitability Revenues were up strongly in the first half while costs and cash outflows fell Circassia Pharmaceuticals PLC - The company is on the right financial trajectory Circassia Pharmaceuticals PLC (LON:CIR) published the road-map to profitability as it reported strong growth in first-half sales alongside a reduction in costs and cash outflows. The respiratory diseases specialist said revenues for the six months ended June 30 were up 40% year-on-year at £27.9mln, with the figure set to more than double to £60-£65mln for the full-year. Annual turnover of £75mln would result in specialty pharma group turning an underlying profit (EBITDA), the company said. At the halfway stage, Circassia posted and a loss before tax and depreciation of £12.4mln, though the deficit narrowed from almost £21mln six months earlier. Cash is key for a business navigating its way to profitability and the firm had £19.8mln as at August 31. The company’s product suite includes NIOX, which helps improve asthma management, and Tudorza for chronic lung conditions. Launch preparations are complete for the recently-approved chronic obstructive pulmonary disease treatment Duaklir in the US. “With our ongoing focus on controlling our cost base and with multiple growth drivers in place, including the imminent launch of Duaklir in the US and our new sales teams in China and Italy focused on growing NIOX revenues, we look forward to further boosting our performance over the rest of the year,” said chief executive Steven Harris. “By building on our performance in the first two months of the second half, we plan to continue our drive towards profitability and our goal of building a self-sustaining specialty pharmaceutical business.” p r o a c t i v e article ADVFN does not allow posting of their links here - bloody ridiculous, fear of competition by censorship
the abbot
26/9/2019
09:09
Good luck to you too @the abbot. IMO it's going lower but takes two to make a market.
spectoacc
26/9/2019
09:07
A simple read to this is AZN has confidence, they will be fully aware of CIR's position with most likeley an open book accounting approach to their relationaship. Either way, good luck with whatever you plan to do SpectoAcc, for my mind and at least at this level, CIR is a buy for me.
the abbot
26/9/2019
08:59
SpectoAcc initiates coverage with a "Bye", until further evidence emerges of progress. Was underwhelmed this morning tbh, & more confused on the AZN situation - which seems to have gone from CIR having to make milestone payments, to CIR drawing down on a 5 year loan from AZN?
spectoacc
26/9/2019
08:53
FinnCap initiates coverage on Circassia as a BUY to 80p Peel hunt reiterate their BUY to 90p Nice to see dual coverage now from brokers and happy with their price targets at a similar level - shows some proper analysis rather than house broking favouritism. My position: I'm a buyer at this level. hTTps://www.ybs.co.uk/sharedealing/company/index.html?company=CIR#view=broker-views
the abbot
26/9/2019
07:58
My most basic view here is we have a company that has put everything in place to accelerate growth. A great example is the 193% revenue growth in China. The AZN payment has agreement through a 5 year loan and looking at the potential revenue stream against the reduction in costs they seem to be achieving, I see no reason why their target to achieving positive EBITDA cannot be met. I guess the benefit to NEW shareholders is that without Woodford, they would not have been able to pickup a share of this company at this price. For LTH I think this could be the catalyst for a turnaround. Full year results will be key but they certainly sound upbeat.
the abbot
26/9/2019
07:52
It's heading in the right direction.
mirabeau
26/9/2019
07:50
On balance a good news story, does the extra 10 million in revenue needed to make ebitda b/e happen before the need for a fund raise? I suspect it just might, still plenty of risk here but credit to Steve and his team for the progress, especially in sorting out the mess that was China imo dyor ofc.
rathean
26/9/2019
07:45
Highlights · 40% revenue growth to £27.9 million in H1 2019 vs £19.9 million H2 2018 · 25% reduction in underlying continuing non-commercial costs to £7.6 million vs £10.1 million H2 2018 · Growth drivers in place to achieve £60 million - £65 million full year 2019 revenues (2018: £48.3 million) · Dramatic reduction in net cash outflow post period end · Strong focus on cost control to continue transition to self-sustainability AstraZeneca collaboration During 2019, Circassia addressed the outstanding consideration relating to its transaction to acquire the US commercial rights to Tudorza® and Duaklir® through a five-year vendor loan provided by AstraZeneca. Under the terms of the companies' agreement, Circassia has now drawn down $125 million, and will access the final $18.3 million R&D payment due to AstraZeneca at the end of 2019. Current liabilities at the end of the period were £109.5 million (31 December 2018: £124.4 million). The decrease is mainly due to the settlement of contingent consideration to AstraZeneca, which has been offset by a loan repayable within five years and is therefore classified as non-current.
the abbot
26/9/2019
07:24
Loss of £19m in H1 – cash of £21m at 30/6 – but £19.8m at 30/8 so annualised rate of cash burn appears to have reduced to £7.2m.
zho
26/9/2019
07:10
Summary and outlook Circassia anticipates significant sales growth during the second half of 2019, with a number of factors expected to contribute to the increase. In particular, the Company expects increased Tudorza(R) revenues following the recent transfer of the product licence and initial Duaklir(R) sales later this year following its imminent launch. The Company also plans to continue its cost control, and with favourable working capital movements on Tudorza(R) sales anticipates a dramatic reduction in net cash outflow. As a result, Circassia looks forward to continuing its trajectory towards self-sustainability, with an ongoing focus on achieving positive EBITDA at approximately GBP75 million annual sales level.'
mirabeau
Chat Pages: 53  52  51  50  49  48  47  46  45  44  43  42  Older
Your Recent History
LSE
CIR
Circassia ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191013 22:51:43